IMPROVE-AD: Randomized trial for uncomplicated Type B Aortic Dissection

The IMPROVE-AD study is funded by the National Heart, Lung, and Blood Institute in the US. The study aims to understand how best to treat type B aortic dissection. It will include up to 1,100 patients from 60 hospitals across the United States and Canada. The trial is powered to demonstrate whether upfront thoracic endovascular repair (TEVAR) is superior to the standard of care of Medical Therapy and intervention when needed during follow up over 4 years. The entire study duration is 7 years with a planned completion in 2030.